Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome

被引:0
作者
Giordano, Salvatore [1 ]
Ielapi, Jessica [2 ]
Salerno, Nadia [2 ]
Cersosimo, Angelica [2 ]
Lucchino, Alessandro [1 ]
Laschera, Alessandro [1 ]
Canino, Giovanni [1 ]
Di Costanzo, Assunta [1 ]
De Rosa, Salvatore [1 ]
Torella, Daniele [2 ]
Sorrentino, Sabato [1 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Div Cardiol, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy
关键词
acute coronary syndrome; proprotein convertase subtilisin/kexin type 9; low-density lipoprotein cholesterol; EARLY POSTINFARCTION PERIOD; CARDIOVASCULAR-DISEASE; HEART-DISEASE; CHOLESTEROL; EVOLOCUMAB; RISK; LDL; ATORVASTATIN; EXPRESSION; IMPACT;
D O I
10.31083/j.rcm2510374
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute coronary syndromes (ACSs) represent a significant global health challenge arising from atherosclerotic cardiovascular disease (ASCVD), with elevated low-density lipoprotein cholesterol (LDL-C) levels being a primary contributor. Despite standard statin therapy, individuals with ACS remain at high risk for recurrent cardiovascular events, particularly in the initial post-ACS period. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), such as evolocumab and alirocumab, offer a potential strategy to reduce LDL-C levels further and mitigate this residual risk. This review delves into the molecular mechanisms, effects on cholesterol metabolism, inflammatory modulation, and clinical outcomes associated with early administration of PCSK9 inhibitors following ACS.
引用
收藏
页数:12
相关论文
共 74 条
  • [1] Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
    Almontashiri, Naif A. M.
    Vilmundarson, Ragnar O.
    Ghasemzadeh, Nima
    Dandona, Sonny
    Roberts, Robert
    Quyyumi, Arshed A.
    Chen, Hsiao-Huei
    Stewart, Alexandre F. R.
    [J]. PLOS ONE, 2014, 9 (09):
  • [2] The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods
    Basiak, Marcin
    Hachula, Marcin
    Kosowski, Michal
    Machnik, Grzegorz
    Maliglowka, Mateusz
    Dziubinska-Basiak, Maria
    Krysiak, Robert
    Okopien, Boguslaw
    [J]. MOLECULES, 2023, 28 (15):
  • [3] Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
    Basiak, Marcin
    Hachula, Marcin
    Kosowski, Michal
    Okopien, Boguslaw
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [4] 2023 ESC Guidelines for the management of acute coronary syndromes
    Byrne, Robert A.
    Rossello, Xavier
    Coughlan, J. J.
    Barbato, Emanuele
    Berry, Colin
    Chieffo, Alaide
    Claeys, Marc J.
    Dan, Gheorghe-Andrei
    Dweck, Marc R.
    Galbraith, Mary
    Gilard, Martine
    Hinterbuchner, Lynne
    Jankowska, Ewa A.
    Juni, Peter
    Kimura, Takeshi
    Kunadian, Vijay
    Leosdottir, Margret
    Lorusso, Roberto
    Pedretti, Roberto F. E.
    Rigopoulos, Angelos G.
    Gimenez, Maria Rubini
    Thiele, Holger
    Vranckx, Pascal
    Wassmann, Sven
    Wenger, Nanette Kass
    Ibanez, Borja
    ESC Sci Document Grp
    [J]. EUROPEAN HEART JOURNAL, 2023, 44 (38) : 3720 - 3826
  • [5] PCSK9 as a Positive Modulator of Platelet Activation
    Camera, Marina
    Rossetti, Laura
    Barbieri, Silvia S.
    Zanotti, Ilaria
    Canciani, Barbara
    Trabattoni, Daniela
    Ruscica, Massimiliano
    Tremoli, Elena
    Ferri, Nicola
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (08) : 952 - 954
  • [6] Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
    Cao, Ye-Xuan
    Li, Sha
    Liu, Hui-Hui
    Li, Jian-Jun
    [J]. BMJ OPEN, 2018, 8 (09):
  • [7] Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study
    Cariou, B.
    Guerin, P.
    Le May, C.
    Letocart, V.
    Arnaud, L.
    Guyomarch, B.
    Pichelin, M.
    Probst, V.
    [J]. DIABETES & METABOLISM, 2017, 43 (06) : 529 - 535
  • [8] Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab®: A prospective cohort study
    Di Minno, Matteo Nicola D.
    Gentile, Marco
    Di Minno, Alessandro
    Iannuzzo, Gabriella
    Calcaterra, Ilenia
    Buonaiuto, Alessio
    Di Taranto, Maria D.
    Giacobbe, Carola
    Fortunato, Giuliana
    Rubba, Paolo O. F.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2020, 30 (06) : 996 - 1004
  • [9] PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
    Ding, Zufeng
    Wang, Xianwei
    Liu, Shijie
    Shahanawaz, Jiwani
    Theus, Sue
    Fan, Yubo
    Deng, Xiaoyan
    Zhou, Sichang
    Mehta, Jawahar L.
    [J]. CARDIOVASCULAR RESEARCH, 2018, 114 (13) : 1738 - 1751
  • [10] PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
    Ding, Zufeng
    Liu, Shijie
    Wang, Xianwei
    Theus, Sue
    Deng, Xiaoyan
    Fan, Yubo
    Zhou, Sichang
    Mehta, Jawahar L.
    [J]. CARDIOVASCULAR RESEARCH, 2018, 114 (08) : 1145 - 1153